Back to All

Diaceutics Names Steve Vitale Managing Director of Analytics, Insights and Strategy Division

1 November, 2015

Appointment Supports Pharma’s Growing Demand for Personalized Medicine related Intelligence and Strategy

Parsippany, NJ, November 18, 2015 – Diaceutics, a dedicated integrator in personalized and precision medicine, enabling the effective combination of therapies and diagnostics into the treatment pathway, today announced industry veteran Steve Vitale has joined the company to lead its Analytics, Insights and Strategy (AIS) division. Mr. Vitale comes to the Diaceutics from TGaS Advisors, LLC where he was Head of the TGaS Marketing benchmark solution.

“We are very excited to add someone of Steve’s caliber and experience to our leadership team,” said Peter Keeling, CEO of the Diaceutics. “His diverse background and proven track record both within pharma and providing solutions to pharma – specifically understanding what is needed to successfully launch a targeted therapy in today’s global marketplace – is a big win for Diaceutics and our clients. Steve is a natural choice to lead our Analytics, Insights and Strategy division.”

With more than 20 years of experience, Mr. Vitale has held several senior roles at GlaxoSmithKline including Innovation Director, US Vaccines, where he spearheaded the creation of the innovation function and drove development of novel services and solutions to remove barriers customers face throughout the immunization process; Marketing Director, Hib / Meningitis Vaccines, where he launched Hiberix® in the US market and led all pre-commercial and marketing activities supporting the MenHibrix® launch. Mr. Vitale also served as Director, Global Commercial Strategy, Cardiovascular / Metabolic where he drove commercial assessments, evolution of product life cycle and market development opportunities for the diabetes franchise.

“The need for increasingly advanced analytics, deeper insights and formal strategies around targeted therapy launches is becoming more and more critical as pharma’s pipelines become more and more targeted,” said Vitale. “The Diaceutics has been leading the way in terms of helping pharma companies understand the challenging dynamics of targeted therapy launches and I look forward to bringing my experience and knowledge to our AIS division.”

Mr. Vitale has an M.BA. from The Tepper School of Business at Carnegie Mellon University in Pittsburgh, PA and BA in Political Science from Amherst College in Amherst, MA.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.